Close Menu

NEW YORK (GenomeWeb) – Investment bank Janney today downgraded Danaher's shares to a Neutral rating from a previous Buy rating, but kept its fair value estimate for the company at $95 per share.

In a research note, analyst Paul Knight said that Danaher "has more work to do on optimizing its portfolio, and we expect smaller organic growth surprises than other peers." In particular, he noted Danaher's 2.5 percent organic growth in the first quarter, which Knight said was the lowest among large cap science peers, such as Thermo Fisher Scientific, Waters, and Agilent Technologies.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.